{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:19:13Z","timestamp":1698297553347},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"vor","delay-in-days":5479,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1992,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thirty\u2010four patients with refractory or recurrent high grade non\u2010Hodgkin's lymphoma (NHL) or acute leukemia were treated with a combination of etoposide, 100 mg\/m<jats:sup>2<\/jats:sup> daily, and ara C, 1 g\/m<jats:sup>2<\/jats:sup> twice daily, for 5 days (VPARAC). This therapy was given in the anticipation that remissions thus achieved would be \u2018consolidated\u2019 with myeloablative therapy supported by bone marrow transplantation (BMT). The complete remission rate (CR) in patients with NHL was 3\/18 (17 per cent) with partial responses (PR) seen in a further four patients, giving an overall response rate of 39 per cent. Four patients (three in CR, one in PR) proceeded to the planned consolidation treatment. Complete remission was achieved in 2\/8 (25 per cent) patients with acute myelogenous leukemia (AML) and in 2\/8 patients with acute lymphoblastic leukemia (ALL). Three of these patients subsequently had myeloablative consolidation therapy with BMT. There were four treatment\u2010related deaths (NHL, two; AML, one; ALL, one). In poor risk patients with high grade NHL and acute leukemia, VPARAC is an effective remission induction programme in 21 per cent of patients. Seven of the original 34 patients received the intended \u2018curative\u2019 therapy, of whom only four are alive and well 1 year later.<\/jats:p>","DOI":"10.1002\/hon.2900100204","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T18:53:44Z","timestamp":1171911224000},"page":"87-94","source":"Crossref","is-referenced-by-count":4,"title":["Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy"],"prefix":"10.1002","volume":"10","author":[{"given":"J. S.","family":"Whelan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Z. S.","family":"Rohatiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. K.","family":"Maccallum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A. L.","family":"Amess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Lister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.8.898"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-5-596"},{"key":"e_1_2_1_4_2","first-page":"160","article-title":"Acute lymphoblastic leukaemia in adults","volume":"12","author":"Clarkson B.","year":"1985","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-757"},{"key":"e_1_2_1_6_2","first-page":"169","article-title":"Treatment of acute lymphoblastic leukaemia in adults","volume":"19","author":"Barnett M. J.","year":"1986","journal-title":"Br. J. Haematol."},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V69.4.1242.1242","article-title":"Improved results of treatment of adult acute lymphoblastic leukaemia","volume":"69","author":"Linker C. A.","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.123.123"},{"key":"e_1_2_1_9_2","first-page":"485","volume-title":"Leukaemic","author":"Rohatiner A. Z. S.","year":"1990"},{"key":"e_1_2_1_10_2","first-page":"60","article-title":"Chemotherapy for large cell lymphoma: a status update","volume":"17","author":"Yi P. I.","year":"1990","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.25"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V73.7.1749.bloodjournal7371749","article-title":"Bone marrow transplantation in the treatment of lymphoma","volume":"73","author":"Armitage J. O.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_13_2","first-page":"431","volume-title":"Leukaemia","author":"Fefer A.","year":"1990"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162402"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04309.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.630"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.133.2.260"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197511)36:5<1560::AID-CNCR2820360504>3.0.CO;2-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905243002105"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-82-5-684"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-6-785"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197910)44:4<1189::AID-CNCR2820440404>3.0.CO;2-O"},{"key":"e_1_2_1_24_2","first-page":"215","article-title":"The use of intermediate and high dose cytosine arabinoside in relapsed and refractory acute leukaemia","volume":"26","author":"Van Broogen H. L.","year":"1987","journal-title":"Neth. J. Med."},{"key":"e_1_2_1_25_2","first-page":"1587","article-title":"A pilot study of high\u2010dose 1\u2010\u03b2\u2010d\u2010arabinofuranosylcytosine for acute leukaemia and refractory lymphoma: clinical response and pharmacology","volume":"42","author":"Early A. P.","year":"1982","journal-title":"Cancer Res."},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1983.1.11.689","article-title":"High\u2010dose cytosine arabinoside in non\u2010Hodgkin's lymphoma","volume":"1","author":"Kantarjian H.","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254596"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90522-9"},{"issue":"3","key":"e_1_2_1_29_2","first-page":"223","article-title":"The use of high\u2010dose cytosine arabinoside for non\u2010Hodgkin's lymphoma","volume":"12","author":"Richards M. A.","year":"1985","journal-title":"Semin. Oncol."},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(75)90099-7"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:6<1284::AID-CNCR2820450604>3.0.CO;2-Q"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(84)90138-X"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.1986.4.7.1089","article-title":"Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphoblastic leukaemia in childhood","volume":"7","author":"Esumi N.","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00570500"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP\u201016: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas F.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435839"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.387"},{"key":"e_1_2_1_38_2","unstructured":"Dhaliwal H. S. Richards M. A. Gregory W. et al.MACOP therapy for advanced high grade non\u2010Hodgkin's lymphoma: identification of prognostic factors. (in preparation)."},{"key":"e_1_2_1_39_2","unstructured":"Radford J. A. Whelan J. Deakin D. Rohatiner A. Z. S. Lister T. A. Crowther D. VAPEC B: a weekly chemotherapy for high grade non\u2010Hodgkin's lymphoma. Early results of a collaborative trial at two centres.4th International Conference on Malignant Lymphoma Lugano June1990."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.407"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_1_42_2","first-page":"256","article-title":"Combination of etoposide, high dose ara\u2010C and solu\u2010medrol with or without platinol in relapsing or resistant lymphoma","volume":"8","author":"Velasquez W.","year":"1989","journal-title":"Proc. ASCO"},{"key":"e_1_2_1_43_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood.V76.7.1293.1293","article-title":"CEPP(B): An effective and well\u2010tolerated regimen in poorrisk, aggressive non\u2010Hodgkin's lymphoma","volume":"76","author":"Chao N. J.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.423"},{"key":"e_1_2_1_45_2","unstructured":"Johnson P. Personal communication."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y"},{"key":"e_1_2_1_47_2","first-page":"413","article-title":"Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant","volume":"65","author":"Armitage J. O.","year":"1981","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900100204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900100204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T21:09:40Z","timestamp":1698095380000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900100204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,3]]}},"alternative-id":["10.1002\/hon.2900100204"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900100204","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,3]]}}}